Ohno, M., Miyakita, Y., Takahashi, M., Igaki, H., Matsushita, Y., Ichimura, K., & Narita, Y. (2019). Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years. Radiat Oncol.

Ohno, Makoto, Yasuji Miyakita, Masamichi Takahashi, Hiroshi Igaki, Yuko Matsushita, Koichi Ichimura, e Yoshitaka Narita. "Survival Benefits of Hypofractionated Radiotherapy Combined With Temozolomide or Temozolomide Plus Bevacizumab in Elderly Patients With Glioblastoma Aged ≥ 75 years." Radiat Oncol 2019.

Ohno, Makoto, et al. "Survival Benefits of Hypofractionated Radiotherapy Combined With Temozolomide or Temozolomide Plus Bevacizumab in Elderly Patients With Glioblastoma Aged ≥ 75 years." Radiat Oncol 2019.